Understanding a potentially new therapeutic target in incurable childhood acute lymphoblastic leukaemia
Dissecting the role of CD133/PROM1 in MLL rearranged acute lymphoblastic leukaemia to develop novel targeted therapy
Understanding how some leukaemia cells survive treatment and cause a relapse
Understanding and therapeutically exploiting clonal evolution in chemo-resistant acute lymphoblastic leukaemia
Stopping ‘cut-and-run’ DNA errors to help treat leukaemia and predict relapse
Towards inhibiting cut-and-run: An aberrant V(D)J recombination reaction that leads to lymphoid cancers
Killing dormant leukaemia cells to stop relapse
Targeting refractory and dormant stem cells in childhood leukaemia
Investigating novel drug combinations for acute myeloid leukaemia
Identifying Combination Therapies Targeting Apoptosis pathways in Paediatric AML (CAuSAL study)
Improving the outlook for children with Philadelphia positive ALL
Unravelling clinical heterogeneity in Philadelphia positive ALL
Can we prevent leukaemia in children?
Modelling prophylactic (microbial) prevention of childhood acute lymphoblastic leukaemia
Using repurposed drugs to repair the damage that causes acute myeloid leukaemia
Targeting mutant NRAS in paediatric AML
Investigating the genetic pathways that control leukaemia growth
RNA helicase DDX3X regulates JAK-STAT signalling in acute lymphoblastic leukaemia